Procter & Gamble said it’s open to an acquisition in the consumer health care category, citing its successful purchase of a Merck business unit in 2018 https://t.co/aiN23Imn21 ...

About Prestige Consumer Healthcare Inc. Prestige Consumer Healthcare markets, sells, manufactures and distributes consumer healthcare products to retail outlets throughout the U.S. and Canada, Australia, and in certain other international markets. The Company's diverse portfolio of brands include Monistat and Summer's Eve women's health products, BC and Goody's pain relievers, Clear Eyes and TheraTears® eye care products, DenTek specialty oral care products, Dramamine motion sickness treatments, Fleet enema ...

On July 11, 2025, Andrew Hill Investment Advisors, Inc. disclosed it sold out its entire Johnson & Johnson (JNJ -0.60%) position, totaling $6.31 million in trades.What happenedAccording to a July 10, 2025 SEC filing, the firm exited its entire position in Johnson & Johnson during Q2 2025, selling all 38,037 shares for $6,308,131 in reported transaction value. Andrew Hill Investment Advisors no longer holds JNJ shares as of June 30, 2025, based on 13F disclosures.What else to knowThe sale represents a full e ...

Core Insights - Johnson & Johnson (NYSE: JNJ) is expected to report earnings of $2.68 per share and sales of $22.86 billion on July 16, 2025, compared to $2.82 per share and $22.45 billion in the same quarter last year [3] - The company has a market capitalization of $378 billion and reported $89 billion in revenue over the past twelve months, with $22 billion in operating profits and $22 billion in net income [4] Historical Performance - Historically, JNJ has delivered positive one-day returns in 55% of cases following earnings announcements over the past five years, with a median positive return of 2.3% and a peak one-day positive return of 6.1% [2][7] - Over the last five years, there have been 20 recorded earnings data points, with 11 resulting in positive and 9 in negative one-day returns [7] - The percentage of positive one-day returns drops to 33% when analyzing data from the last three years [7] Trading Strategies - Traders may consider taking a position prior to the earnings release based on historical data or wait for the earnings to be disclosed to analyze immediate and medium-term returns [6] - A correlation analysis between short-term and medium-term returns can guide trading choices, particularly if 1D and 5D returns demonstrate a strong correlation [8]

NEW YORK, July 10, 2025 (GLOBE NEWSWIRE) -- OTC Markets Group Inc. (OTCQX: OTCM), operator of regulated markets for trading 12,000 U.S. and international securities, today announced Reckitt Benckiser Group plc (“Reckitt”) (LSE: RKT; OTCQX: RBGLY, RBGPF), the company behind some of the world's best-loved consumer health and hygiene brands, has qualified to trade on the OTCQX® Best Market. Reckitt upgraded to OTCQX from the Pink® market. Reckitt begins trading today on OTCQX under the symbols “RBGLY” and “RBG ...

Study highlights how AI tools like ChatGPT are shaping reputation and consumer perception of leading OTC brandsCAMPBELL, Calif. and NEW YORK, July 01, 2025 (GLOBE NEWSWIRE) -- Campbell, California and New York City – July 1st, 2025 – LiveWorld, Inc. (OTC Markets: LVWD), a pioneer in social-first digital engagement and integrated human-AI solutions, today announced the release of the first-ever AI Brand Reputation Index for over-the-counter (OTC) consumer healthcare brands. The groundbreaking study delivers ...

Core Insights - Zacks Premium offers various tools for investors to enhance their stock market strategies and confidence [1] - The Zacks Style Scores provide a framework for evaluating stocks based on value, growth, and momentum characteristics [2][3][4][5][6] Zacks Style Scores - The Style Scores categorize stocks into four types: Value Score, Growth Score, Momentum Score, and VGM Score, each focusing on different investment strategies [3][4][5][6] - Value Score emphasizes finding undervalued stocks using metrics like P/E and Price/Sales ratios [3] - Growth Score assesses stocks based on projected earnings and sales growth [4] - Momentum Score identifies stocks with favorable price trends and earnings outlooks [5] - VGM Score combines all three styles to highlight stocks with the best overall potential [6] Zacks Rank - The Zacks Rank is a proprietary model that uses earnings estimate revisions to help investors build successful portfolios [7] - Stocks rated 1 (Strong Buy) have historically outperformed the market, with an average annual return of +25.41% since 1988 [8] - There are over 800 stocks rated 1 or 2, making it essential for investors to utilize Style Scores to narrow down choices [9] Stock Example: Prestige Consumer Healthcare (PBH) - Prestige Consumer Healthcare Inc. develops and sells OTC healthcare products across various markets [11] - PBH holds a 3 (Hold) rating on the Zacks Rank and has a VGM Score of B, indicating solid potential [12] - The company has a forward P/E ratio of 17, making it attractive for value investors [12] - Recent upward revisions in earnings estimates suggest positive momentum, with the Zacks Consensus Estimate for fiscal 2026 at $4.76 per share [12] - With strong Value and VGM Style Scores, PBH is recommended for investors' consideration [13]

Group 1 - Haleon has appointed Carl Haney as Chief Research & Development Officer, effective August 1, 2025, following Franck Riot's departure after six years [1][2] - Carl Haney brings 13 years of experience from Estée Lauder and over 20 years from Procter & Gamble, focusing on innovation and R&D in consumer businesses [1][2] - The CEO of Haleon, Brian McNamara, expressed confidence in Haney's ability to drive transformative innovation and contribute to the company's new "Win as One" strategy [2][3] Group 2 - Franck Riot's contributions to Haleon were acknowledged, particularly in advancing the innovation agenda during the company's transition [3] - Carl Haney expressed enthusiasm about joining Haleon at a pivotal time, emphasizing the importance of R&D in achieving the company's goals of enhancing everyday health [3] - Haleon is positioned as a global leader in consumer health, with a diverse product portfolio across six major categories, including Oral Health and Pain Relief [4]

Group 1: Dividend Stocks Overview - Dividend stocks are essential for income generation and can provide reliable income that supplements or compounds growth [1] - High-quality dividend stocks combine attractive yields with stock price growth, enhancing total returns for investors [2] Group 2: Exxon Mobil - ExxonMobil has a dividend yield of 3.50% with an annual dividend of $3.96 and a 42-year track record of dividend increases [3][4] - The company maintains a dividend payout ratio of 52.52% and generates significant free cash flow, supporting its dividend commitments and stock buybacks [4] - A major revenue driver for ExxonMobil is its oil projects in Guyana, despite ongoing arbitration with Chevron over a stake in the project [5] Group 3: Hasbro - Hasbro's stock has increased by approximately 21% in 2025, nearing a historical resistance level [6] - The company offers a dividend yield of 4.12% with an annual dividend of $2.80 and a payout ratio of 92.41% [8][10] - Hasbro is restructuring to focus on high-margin licensing deals, which will help unlock value in its iconic brands [9] - Analysts have a consensus price target of $81.25 for Hasbro, indicating a potential upside of 19.6% from its recent closing price [10] Group 4: Perrigo - Perrigo has a dividend yield of 4.41% with an annual dividend of $1.16 and a 23-year history of dividend increases [11] - The stock has seen a modest increase of 2.45% in 2025 but remains range-bound as investors seek its attractive dividend [12] - Perrigo specializes in over-the-counter medications, and its performance may benefit from consumers seeking value alternatives amid economic pressures [13]

Core Insights - Hims & Hers Health, Inc. has established itself as a leading direct-to-consumer healthcare platform through a subscription-based revenue model, achieving 2.4 million subscribers as of Q1 2025, a 38.4% year-over-year increase [1][7] - The company reported $576.4 million in online revenue, reflecting a 115.3% year-over-year growth, contributing nearly all of its total revenues of $586 million [1][7] - The Monthly Online Revenue per Average Subscriber increased to $84, a 52.7% rise from $55, indicating deeper customer engagement and upselling of premium services [2] Subscription Model and Customer Engagement - Hims & Hers has a robust pipeline with $110.8 million in deferred revenues as of March 2025, highlighting the strength of its subscription model [2][7] - Recent partnerships with Novo Nordisk and NovoCare Pharmacy have expanded access to GLP-1 weight loss offerings, enhancing the value of the subscription model [3] - The company’s subscription model is designed to provide continuous, personalized care, which is crucial for long-term growth and customer loyalty [3] Industry Comparisons - LifeMD, Inc. reported that 86% of its Q1 2025 revenues came from recurring subscription services, with 291,000 active subscribers, showcasing strong demand [4] - Doximity, Inc. generates over 95% of its revenue from enterprise subscription contracts, with a net revenue retention rate of 119%, indicating strong customer expansion [5] Financial Performance and Valuation - Hims & Hers shares have surged 138.1% year to date, outperforming the industry average gain of 29.7% [6] - The forward 12-month price-to-sales ratio for Hims & Hers is 5X, lower than the industry average of 6.3X but higher than its five-year median of 2.6X [8] - The Zacks Consensus Estimate for Hims & Hers' 2025 earnings per share suggests a 170.4% improvement from 2024 [10]